Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

- Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants - Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a 9.3-fold IgG rise and a 19.9-fold ACE2 inhibition increase after booster dose - Immune responses in adolescents were 2- to 4-fold higher than adults against broad array of variants of interest and variants of concern - Development of Omicron-specific vaccine on track for initiation of GMP manufacturing in early January - Company to host investor conference call today from 4:30 - 5:00 pm ET GAITHERSBURG, Md., Dec. 22, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced initial data evaluating the immune response of its COVID-19 vaccine, NVX-CoV2373, against the Omicron variant as well as additional data from its ongoing Phase 2 boost study.

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies

New York, New York--(Newsfile Corp. - December 22, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than January 18, 2022 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Novavax, Inc. ("Novavax") (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"). The...

NOVAVAX, INC. (NVAX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Novavax, Inc.

BioNTech SE

Ocugen, Inc.

Decreasing concerns about the omicron variant are leading to declining prices for these vaccine stocks.

Why BioNTech, Novavax, and Ocugen Stocks Are Slipping Today

Novavax (NVAX) initiates a phase III study to evaluate the booster dose of its COVID vaccine. WHO recommends administering the company's COVID vaccine booster to immunocompromised persons.

Novavax (NVAX) Commences COVID-19 Vaccine Booster Study

For Novavax, the vaccine approval is only the beginning. The company has a lot working in its favor and the sky is the limit for NVAX stock.

Novavax Has Finally Received The Much-Awaited Approval And The Stock Is Set To Soar

Boston, Massachusetts--(Newsfile Corp. - December 22, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ: NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email investors@tenlaw.com or call...

Thornton Law Firm Reminds Novavax, Inc. (NVAX) Investors of Securities Class Action Lawsuit

Novavax Inc's (NASDAQ: NVAX) first booster doses of NVX-CoV2373 have been administered in an extension of PREVENT-19 Phase 3 trial.  All PREVENT-19 trial participants are now eligible to receive a third booster dose of NVX-CoV2373.

Novavax Initiates Phase 3 COVID-19 Vaccine Booster Study

AbbVie

Pfizer

These three biotech stocks have performed amazingly well of late and are more than likely to perform even better next year. The post 3 of the Best Biotech Stocks for 2022 to Buy Now appeared first on InvestorPlace.

3 of the Best Biotech Stocks for 2022 to Buy Now

Abbott Labs

Cerner

Veracyte

Could these health care stocks be worth looking out for as the new year approaches?

Best Long Term Stocks To Buy? 4 Health Care Stocks For Your Watchlist

GAITHERSBURG, Md., Dec. 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the first booster doses of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant, have been administered in an extension of the company's PREVENT-19 pivotal Phase 3 clinical trial.

Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study

- WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends primary two-dose vaccination series of NVX-CoV2373 in persons aged 18 and older - SAGE recommends additional third dose of NVX-CoV2373 administered to immunocompromised persons - Recommendation follows grant of WHO Emergency Use Listing for Novavax' vaccine GAITHERSBURG, Md., Dec. 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) has published its interim recommendations for use of NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant.

World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine

NEW YORK, Dec. 21, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline. SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novavax, Inc. Investors With Losses to Secure Counsel Before Important January 11 Deadline in Securities Class Action - NVAX

Novavax (NVAX) secures approval for its COVID vaccine in the European Union. Following EU approval, WHO grants second emergency use listing to the company's COVID vaccine.

Novavax (NVAX) COVID Vaccine Gets EU Nod, 2nd Listing by WHO

On Monday, the European Commission announced that it has granted Novavax, Inc. ( NVAX , Financial) a Conditional Marketing Authorization (CMA) for the sale of its Covid-19 vaccine Nuvaxovid to the European Union (EU) countries. So far, Nuvaxovid is the fifth vaccine approved in the EU against the Covid-19 virus.

Novavax's Covid-19 Vaccine Is Finally Approved

2022 will be a watershed year for the company in more ways than one.

3 Things About Novavax That Smart Investors Know

Moderna

It had much to do with a certain Greek letter.

Why Some Coronavirus Stocks Plunged Today

In what should have been good news for the stock, Novavax Inc (NASDAQ: NVAX) is down over 6% on the day on heavy volumes with over 10 million shares traded (double the 10 day average) and over 57,000 options traded. This is in spite of the fact the stock received conditional approval in Europe for its COVID-19 vaccine.

Novavax Shares Fall On Heavy Options Volume Following COVID Vaccine Approval By EU

The European Commission has granted conditional marketing authorization to Novavax Inc's (NASDAQ: NVAX) Nuvaxovid COVID-19 Vaccine for active immunization to prevent COVID-19 in individuals 18 years of age & older.  The authorization follows the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation today to authorize the vaccine.

Novavax's COVID-19 Vaccine Scores Conditional Approval In Europe

Vaccine stocks aren't enjoying a good morning today, but there's plenty of reason to suspect that they are in for a better year in 2022. The post MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?

MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?

- Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) listed for emergency use by the WHO - EUL for Nuvaxovid complements listing for Novavax vaccine manufactured and marketed by Serum Institute of India as Covovax™ - EUL by WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility GAITHERSBURG, Md., Dec. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has granted a second Emergency Use Listing (EUL) for NVX-CoV2373, Novavax' recombinant protein nanoparticle COVID-19 vaccine with Matrix-M™ adjuvant, for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine

Novavax's (NVAX) COVID-19 vaccine gets approval from WHO for emergency use listing. The vaccine is now pre-qualified for supply to numerous countries participating through the COVAX facility.

Novavax (NVAX) COVID Jab Gets WHO Nod for Emergency Use Listing

Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use in Europe Novavax and the European Commission previously announced an advance purchase agreement for up to 200 million doses through 2023 Authorization follows positive recommendation by European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) GAITHERSBURG, Md., Dec. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

If confirmed by the EU's executive commission, the Novavax shot will become the fifth option for Europeans looking to get the jab.

Novavax Covid-19 Vaccine Wins Approval From European Union Regulator

Novavax Inc (NASDAQ: NVAX) is expected to start delivering its COVID-19 vaccines to the European Union in Q1 of 2022, Reuters reported citing an EU source. The drug regulator met on Monday to decide whether to approve the shot.

Novavax To Possibly Kickstart COVID-19 Vaccine Delivery To EU In Q1 2022: Source

A new strategy that focuses on international markets for its Covid-19 vaccine appears to be paying off for U.S. drug maker Novavax. The post NVAX Stock Alert: 2 Big Reasons Novavax Is Shooting Higher Today appeared first on InvestorPlace.

News for Novavax Stock (NVAX)